ARVO 2024

I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

Medical Materials

Agenda

Coming soon

04:30 PM

Duration 30mins Seattle, Washington

Automated Segmentation of Hard Exudates Using SD-OCT in Patients with Diabetic Macular Edema from the Phase 2b ALTIMETER Study

Maunz A, Parian-Scherb M, Cohen Y, Bachmeier I, Yu S, Gibson K, Mar F, Xue Z, Glittenberg C

Ophthalmology | Diabetic Macular Edema

03:00 PM

Duration 105mins Seattle, Washington

Defining the Role of Angiopoietin-2 in Vascular Destabilization Using Primary Human Vasculature Models

Westenskow P, Stoll, R, Spielmann A, Kim B, Ragelle H

Ophthalmology | Neovascular Age Related Macular Degeneration - Diabetic Macular Edema

Duration 105mins Seattle, Washington

Extended treatment outcomes and the potential for Q20W dosing with faricimab▼ in nAMD: a post hoc analysis of the pivotal TENAYA/LUCERNE trials

Storey P, Koh A, Singer M, Hill L, Kotecha A, Margaron P

Ophthalmology | Neovascular Age Related Macular Degeneration

03:30 PM

Duration 105mins Seattle, Washington

Faricimab▼ treatment outcomes with extended dosing and potential for Q20W intervals in DME: post hoc analysis of the 96-week phase 3 YOSEMITE/RHINE trials

Adam M, Gibson K, Sim D, Amador M, Hill L, Singer M

Ophthalmology | Diabetic Macular Edema

Duration 105mins Seattle, Washington

Deep learning to identify diffuse retinal thickening (DRT) on optical coherence tomography (OCT)

Dimitrios Damopoulos, Tom Albrecht, Ali Valcarcel, Derrek Hibar, Mike Chen, Dinah Chen, Vivian Look, Vivide Chang, Daniela Ferrara, Huanxiang Lu

Ophthalmology | Diabetic Macular Edema - Neovascular Age Related Macular Degeneration

10:00 PM

Duration 105mins Seattle, Washington

Longitudinal Quantitative Ultra-Widefield Fluorescein Angiography Leakage Dynamics in Patients With Uveitic Macular Edema Following Intravitreal Anti–IL-6 Therapy With Vamikibart

Cakir Y, Matar K, Cetin H, Amine R, Bonnay M, McConville C, Srivastava S, Pauly-Evers M, Holmes W, Barekati Z, Storti F, Fauser S, Mesquida M, Sharma S, Ehlers J

Ophthalmology | Uveitis

Duration 105mins Seattle, Washington

Intravitreal Interleukin-6 Inhibition With Vamikibart in Sarcoidosis-Associated Uveitis

Pauly-Evers M, Barekati Z, Storti F, Holmes W, Steeples L, Haskova Z, Lin P, Sharma S, Fauser S, Mesquida M

Ophthalmology | Uveitis

Duration 105mins Seattle, Washington

Deep Learning-Based Optical Coherence Tomography Segmentation of Retinal Fluids and Layers Using Multi-Grader Annotations

Pla Alemany S, Albrecht T, Valcarcel A, Hibar D, Chen M, Chen D, Look V, Chang V, Ferrara D, Lu H

Ophthalmology | Age Related Macular Degeneration - Diabetic Macular Edema

Duration 105mins Seattle, Washington

Predicting Geographic Atrophy Growth Rate With Clinical and Derived Imaging Features

Julia Cluceru, Ondrej Slama, Neha Anegondi, Simon S Gao, Daniela Ferrara, Michel Friesenhahn, Christina Rabe

Ophthalmology | Geographic Atrophy

Duration 105mins Seattle, Washington

IL-6 inhibition with vamikibart in patients with uveitic macular edema: phase 3 MEERKAT and SANDCAT trials

Suhler E, Steeples L, Elze M, Macgregor L, Silverman D, Haskova Z

Ophthalmology | Uveitis

Duration 105mins Seattle, Washington

Generalizability of foundation models for geographic atrophy (GA) lesion segmentation in fundus autofluorescence (FAF)

Gros E, McLeod M, Kikuchi Y, Cluceru J, Anegondi N, Gao S, Rabe C, Ferrara D, Yang Q

Ophthalmology | Geographic Atrophy

Duration 15mins Room 6E (Seattle Convention Center - Arch Building)

Real-World Clinical and Anatomical Outcomes in Patients With Neovascular Age-Related Macular Degeneration Treated With Faricimab▼: The FARETINA-AMD Study

Tabano D, Ko S, Borkar D, Leng T, Ali F, Shaia J, Myers R, LaPrise A, Singh R

Ophthalmology | Neovascular Age Related Macular Degeneration

03:30 PM

Duration 105mins Seattle, Washington

Volumetric Fluid Dynamics Using Machine-Learning Augmented Analysis in Patients With Uveitic Macular Edema Receiving Vamikibart in the DOVETAIL Study

Matar K, Cakir Y, Cetin H, Amine R, Bonnay M, McConville C, Srivastava S, Pauly-Evers M, Holmes W, Barekati Z, Storti F, Fauser S, Mesquida M, Sharma S, Ehlers J

Ophthalmology | Uveitis

Duration 105mins Seattle, Washington

Longitudinal Quantitative Anterior Chamber Cell Analysis Following Vamikibart Intravitreal Therapy in Patients With Uveitic Macular Edema From the DOVETAIL Clinical Trial

Sharma S, Hamdan A, Chen C, Le P, Baynes K, Pauly-Evers M, Holmes W, Barekati Z, Storti F, Fauser S, Mesquida M, Srivastava S, Singh S

Ophthalmology | Uveitis

Duration 105mins Seattle, Washington

Efficacy, safety, and durability of faricimab▼ in macular edema due to retinal vein occlusion: 72-week results from the BALATON and COMINO trials

Ghanchi F, Abreu F, Arrisi P, Kotecha A, Liu Y, Paris L, Retiere A, Willis J

Ophthalmology | Retinal Vein Occlusion

Duration 105mins Seattle, Washington

Aqueous Humor Interleukin-6 Levels in Uveitic Macular Edema: Baseline Characteristics From the Phase 1 DOVETAIL Study

Barekati Z, Holmes W, van Donge T, Pauly-Evers M, Jordan G, Sickert D, Peck R, Willen D, Passemard B, Fauser S, Mesquida M, Storti F

Ophthalmology | Uveitis

08:15 PM

Duration 105mins Seattle, Washington

Predicting functional outcomes for different treatment durations of faricimab in diabetic macular edema (DME)

Kikuchi Y, Abderezaei J, McLeod M, Chen C, Benech AC, Ferrara D, Anegondi N, Yang Q

Ophthalmology | Diabetic Macular Edema

10:00 PM

Duration 15mins Room 6E (Seattle Convention Center - Arch Building)

Port Delivery System with ranibizumab (PDS) met primary endpoint and key secondary outcomes with >75% of patients preferring PDS treatment in phase 3 Pavilion trial for diabetic retinopathy (DR)

Latkany P, Regillo C, Wykoff C, Chang M, Emanuelli A, Holekamp N, Malhotra V, Howard D, Santhanakrishnan A, Wetzel-Smith M, Quezada-Ruiz C, Pieramici D

Ophthalmology | Diabetic Retinopathy

Duration 15mins Room 6E (Seattle Convention Center - Arch Building)

Real-world treatment patterns and outcomes in the first 6 and 12 months of faricimab▼ use among eyes with neovascular age-related macular degeneration (nAMD) in the UK: FARWIDE-nAMD

Varma D, Talks J, DeSalvo G, Patel P, DeSilva S, Gale R, McKibbin M, Chi G, James N, Rothwell A, Shah N, Downey A, Dodds M, Dayal P

Ophthalmology | Neovascular Age Related Macular Degeneration

10:30 PM

Duration 15mins Room 6E (Seattle Convention Center - Arch Building)

Impact of Early Intraretinal Fluid Reduction on One-Year Outcomes in Diabetic Macular Edema

Wang Y, Hibar D, Maunz A, Lu H, Albrecht T, Gibson K, Willis J, Chang D, Litts K

Ophthalmology | Diabetic Macular Edema

03:00 PM

Duration 105mins Seattle, Washington

Retinal vasculitis with or without retinal vascular occlusion among eyes with nAMD or DME treated with IVT agents as recorded in the Vestrum database

Patel S, Chi G, Aggarwal N, Amador M, Boucher N, Chang SC, Patel V, Sharma S, Zarbin M

Ophthalmology | Neovascular Age Related Macular Degeneration - Diabetic Macular Edema

Duration 105mins Seattle, Washington

Clinical pearls from the TENAYA/LUCERNE trials of faricimab▼ in patients with nAMD

Haug S, Amador M, Kotecha A, Margaron P, Stoilov I, Tang Y

Ophthalmology | Neovascular Age Related Macular Degeneration

Duration 105mins Seattle, Washington

Greater reduction in pigment epithelial detachment size in TENAYA/LUCERNE with faricimab▼ 6.0 mg vs aflibercept 2.0 mg during head-to-head dosing in patients with nAMD

London N, Khanani A, Lai T, Lim J, Kotecha A, Margaron P, Patel S, Souverain A, Willis J, Yang M

Ophthalmology | Neovascular Age Related Macular Degeneration

Duration 105mins Seattle, Washington

Towards automated optical coherence tomography (OCT) data analysis for a real-world diabetic macular edema (DME) treatment cohort

Talks J, Peto T, Wang X, Gershon A, Menon G, Ghanchi F, Chen X, Look V, Lu H, Chen M, Ferrara D, Chi G, Yang Q

Ophthalmology | Diabetic Macular Edema

Duration 105mins Seattle, Washington

Faricimab treatment response prediction in diabetic macular edema (DME) using deep learning on optical coherence tomography (OCT) and clinical data

McLeod M, Abderezaei J, Kikuchi Y, Chen C, Benech AC, Ferrara D, Anegondi N, Yang Q

Ophthalmology | Diabetic Macular Edema

06:45 PM

Duration 105mins Seattle, Washington

Greater reduction in hard exudates with faricimab▼ vs aflibercept in patients with DME: biomarker results from the phase 3 YOSEMITE/RHINE trials

Goldberg R, Amador M, Dinah C, Gibson K, Glittenberg C, Maunz A, O'Leary O, Rahimy E, Uschner D

Ophthalmology | Diabetic Macular Edema

Duration 105mins Seattle, Washington

Key clinical and anatomic outcomes from the YOSEMITE/RHINE trials of faricimab▼ in patients with DME

Manoharan N, Amador M, Willis J,Stoilov I, Mar F, Gibson K, Abreu F

Ophthalmology | Diabetic Macular Edema

Duration 105mins Seattle, Washington

Real-World Treatment Patterns and Outcomes in the First 6 and 12 Months of Faricimab▼ Use Among Eyes With Diabetic Macular Edema (DME) in the UK: FARWIDE-DME

Reynolds R, Peto T, Bailey C, Downey L, Kiire C, Pearce I, Sivaprasad S, Chi G, James N, Rothwell A, Shah N, Downey A, Dodds M, Dayal P

Ophthalmology | Diabetic Macular Edema

Duration 105mins Seattle, Washington

Treatment outcomes with anti-VEGF therapy for retinal vein occlusion: an analysis of real-world data from 16 UK sites

Dinah C, Dodds M, Arrisi P, Pereira L, Lake A, Nielsen P, Holdsworth J, Saffar I, Chi G

Ophthalmology | Retinal Vein Occlusion

Duration 105mins Seattle, Washington

Efficacy and Safety of Faricimab▼ in ALTIMETER: A Trial Exploring Biomarkers of Ang-2 Inhibition in Patients With DME

Gibson K, Dang S, Amador M, Dieckmann A, Glittenberg C, Kotak A, Mar F, Souverain A, Titz B, Vujosevic S, Fawzi A

Ophthalmology | Diabetic Macular Edema

Duration 105mins Seattle, Washington

Real-world clinical and anatomical outcomes in patients with diabetic macular edema treated with faricimab▼: The FARETINA-DME study

Borkar D, Tabano D, Ko S, Leng T, Shaia J, Myers R, LaPrise A, Ali F, Singh R

Ophthalmology | Diabetic Macular Edema

Duration 105mins Seattle, Washington

Elevatum study design and rationale: a phase 4 trial of faricimab▼ (VABYSMO) in underrepresented patients with DME

Brown J, Cunningham M, Coney J, Scott A, Amador M, Chang J, Yang M, Stoilov I, Gonzalez L

Ophthalmology | Diabetic Macular Edema

Duration 105mins Seattle, Washington

Port Delivery System with ranibizumab (PDS) stabilizes retinal nonperfusion and macular leakage: results from Pagoda and Pavilion phase 3 trials in diabetic macular edema (DME) and diabetic retinopathy (DR)

Wirthlin R, Gill M, Howard D, Menezes A, Rahman S, Latkany P

Ophthalmology | Diabetic Retinopathy

Duration 105mins Seattle, Washington

Port Delivery System With Ranibizumab (PDS) in diabetic macular edema (DME): additional primary analysis results of the phase 3 Pagoda trial

Malhotra V, Klufas M, Marcus D, Graff J, Campochiaro P, Rahman S, Latkany P, Gune S, Lin S, DeGraaf S, Bobbala A, Rabena M, Quezada-Ruiz C, Khanani A

Ophthalmology | Diabetic Retinopathy

Duration 105mins Seattle, Washington

Pharmacokinetic (PK) profile of the Port Delivery System with ranibizumab (PDS) in the phase 3 Pagoda and Pavilion trials

Heinrich D, Wolfe J, Dhoot D, Ding HT, Hyung S, Latkany P, Maass K, Rahman S, Hsu J

Ophthalmology | Diabetic Retinopathy

I am a healthcare professional

Notice

Cookies

External site

ARVO 2024